|Articles|November 15, 2002
- BioPharm International-11-01-2002
- Volume 15
- Issue 11
You Have Failed . . . A Case Study in Warning Letter Remediation
by Joseph Noferi, Edward R. Arling, Ralph L. Dillon, and Mikael Blomqvist, Pharmacia An FDA Warning Letter can be a business disaster. This case study tracks a company from receipt of an FD 483 ? that did not find contamination, but only the potential for contamination ? to 18 months later when the facility received a clean bill of health. What it did to get there ? and what it learned ? may keep your site from losing its operating freedom.
Advertisement
Articles in this issue
about 23 years ago
Inside Washington: Major Changes Ahead for FDAabout 23 years ago
Bioinformatics Databases ? Questions of Copyrightabout 23 years ago
European Editor's Report ? An Industry Comes of Ageabout 23 years ago
Guest Editorial: Back to the Beginningabout 23 years ago
Survival Guide to FDA Inspections: Part 3, Responding to ObservationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
CDC Revises Childhood Immunization Schedule, Shifting Demand Dynamics
2
New AI Oncology Alliance Highlights Industry Push for Scalable Genomics
3
Industry Outlook 2026: Biopharma Braces for Economic Upheaval While Eyeing AI-Driven Transformation (Part 1)
4
What Are the Benefits of Single-Use in CGT Manufacturing?
5
